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Abstract 
Solitary neurofibromal colonic polyps are a rare entity, particularly outside the setting of 
neurofibromatosis type 1. The clinical significance of such lesions has not yet been 
established. Though typically benign tumors, neurofibromas have been reported to undergo 
malignant transformation, with an increased risk of malignancy when associated with 
neurofibromatosis. In this case report, we present the rare case of a man found to have an 
isolated colonic neurofibroma without any personal/family history or clinical features of 
neurofibromatosis. A 59-year-old man with a history of dyslipidemia and degenerative joint 
disease presented for a routine screening colonoscopy. The colonoscopy revealed no 
abnormalities except a 3 mm transverse colon polyp and another 4 mm polyp in the 
descending colon. Biopsy results showed the descending colonic polyp to be a tubular 
adenoma; however, multiple levels of the 3 mm transverse colon polyp revealed interlacing 
bundles of spindle cells extending into the lamina propria with comma-shaped nuclei 
consistent with findings seen in neurofibroma. Isolated colonic neurofibromas are rare and 
understudied. While they are usually benign, they may undergo malignant transformation, 
especially when associated with neurofibromatosis. Thus, patients presenting with isolated 
neurofibromas should be followed for development of neurofibromatosis and malignancies. 
 
Introduction 
Neurofibromas typically are benign nerve sheath tumors of the peripheral nervous 
system, arising from Schwann cells, classically associated with neurofibromatosis 
type 1 (NF1, von Recklinghausen’s disease). Two types of neurofibromas are known to 
develop in NF1: superficial dermal or cutaneous neurofibromas, composed of a single 
peripheral nerve, and deep plexiform neurofibromas, which involve multiple nerve  
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fascicles. Dermal neurofibromas typically arise in the second decade of life, often 
coinciding with the appearance of puberty. Plexiform neurofibromas, on the other 
hand, are typically congenital lesions and tend to grow mainly in the first decade of life. 
Unlike dermal neurofibromas, plexiform neurofibromas on rare occasions have been 
known to undergo malignant transformation and to develop into malignant peripheral 
nerve sheath tumors, which are aggressive, almost uniformly fatal cancers [1, 2]. About 
10% of patients with NF1 are seen to develop these tumors, either from a plexiform 
neurofibroma or without such precursors [3]. 
NF1 is a common neurocutaneous disorder with an incidence of approximately 1 in 
3,000 individuals [4]. It is an autosomal dominant disorder with few cases of sporadic 
inheritance, caused by any of a number of mutations of the Nf1 gene, mapped on 
chromosome 17q11.2. Nf1 is a tumor suppressor gene and produces the protein 
neurofibromin, which in turn is responsible for downregulating Ras, another cell 
protein that is thought to promote cell growth and proliferation [2, 5]. Increased risk of 
tumorigenesis is only seen in the homozygous state [6]. Nf1 has a high penetrance, and 
so most patients with the mutation have some clinical features. Current genetic testing 
is able to identify 95% of Nf1 mutations [7]. However, genetic testing is usually 
unnecessary, since clinical features can establish the diagnosis in about 95% of cases.  
According to the NIH, two of the following diagnostic criteria should be present to 
make the diagnosis of NF1: ≥6 café au lait macules, ≥2 neurofibromas of any type or 
1 plexiform neurofibroma, freckling in the axillary or inguinal regions, optic glioma, 
≥2 iris hamartomas (Lisch nodules), bony lesions (pseudoarthrosis), or a first-degree 
relative with NF1. This condition has variable clinical expressions with manifestations 
involving many systems, such as the skin, eyes, bones, nervous system and 
gastrointestinal tract. The disease is equally prevalent in all ethnic groups.  
Gastrointestinal involvement has been documented in 25% of patients with NF1, 
mostly involving the stomach and small intestine [8, 9]. The involvement consists of 
(1) ganglioneuromas: hyperplasia and hypertrophy of the nerve plexuses and 
ganglionic cells in the mucosa, and/or (2) neurofibromas: hyperplasia of neuronal cells 
in the submucosa, muscularis propria or even from the serosa. Sometimes it is also 
associated with gastrointestinal stromal tumors with different degrees of neuronal and 
smooth muscle differentiation [8, 10]. 
Case Report 
A 59-year-old black man with a history of controlled dyslipidemia, hypertension, depression, 
benign prostatic hyperplasia, erosive gastritis, chronic pain syndrome and degenerative joint disease 
presented for a routine screening colonoscopy. His medical history was also significant for bilateral 
hydroceles and one previous hospitalization 6 years before for community-acquired pneumonia. His 
medications included aspirin 81 mg daily, finasteride 5 mg daily, risperidone 6 mg daily, trazedone 
100 mg daily, fluoxetine 40 mg daily, hydrochlorothiazide 25 mg daily, omeprazole 20 mg daily, and 
tramadol 50 mg three times per day. He did not have any significant history of abdominal pain or 
bloating, diarrhea or constipation, or any melena or hematochezia. The patient denied any recent 
episodes of fevers, chills, nausea, or vomiting. He reported a stable appetite and weight. He had no 
history of alcohol, smoking, or drug abuse. His family history did not include any neurofibromatosis or 
any gastrointestinal malignancies. Physical examination of the head, neck, lungs, heart, skin and other 
systems did not reveal any significant findings. Ophthalmological examination revealed no Lisch  
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nodules. Laboratory examinations, including a complete blood count, metabolic panel, hepatic panel 
and coagulation tests were all within normal limits.  
On colonoscopic examination, a 3 mm polyp was found in the transverse colon (fig. 1) and another 
4 mm polyp in the descending colon; both were biopsied. The remainder of the colonoscopy did not 
reveal any additional abnormal macroscopic pathology. Histological examination of the descending 
colonic polyp revealed findings consistent with a tubular adenoma; however, multiple levels of the 
3 mm transverse colon polyp revealed interlacing bundles of spindle cells extending into the lamina 
propria with comma-shaped nuclei consistent with findings seen in neurofibroma (fig. 2). Subsequent 
immunohistochemical stains were performed on the specimen, which disclosed that S100 was 
expressed in the majority of the cell nuclei, also compatible with neurofibroma. CD117 staining was 
performed twice but had to be voided because of tissue loss. 
Discussion 
In this case, the patient had no personal or familial history of neurofibromatosis, 
nor did he have any of the physical manifestations that define NF1. He presented for 
routine screening colonoscopy that detected two polyps, with subsequent histology 
revealing a neurofibroma, confirmed by S100 staining. This is the fourth reported case 
of isolated colonic neurofibroma in a patient without NF1, and only the second one 
found in an asymptomatic patient undergoing routine colorectal cancer screening  
[11–13]. Unfortunately, this patient was lost to follow-up and no repeat colonoscopies 
were performed. It was discovered later that he died of complications related to an 
aggressive lymphoma. 
The clinical significance of isolated, intestinal neurofibromas has not been 
well established. No consensus has yet been reached in the medical community as 
to whether such lesions represent different phenotypic manifestations of 
neurofibromatosis or separate and distinct entities entirely [14]. Though typically 
benign lesions, they have been reported to undergo malignant transformation, 
particularly when associated with NF1 and in larger, plexiform lesions [15]. Though 
uncommon, there are reports in the literature of neurofibromas and nerve sheath 
tumors presenting as lymphomas [16, 17].  
Gastrointestinal neurofibromas are usually asymptomatic, but may present with 
bleeding, anemia, or signs or symptoms of obstruction. Indications for evaluation of 
gastrointestinal complications in the setting of NF1 include unexplained anemia, weight 
loss, gastrointestinal bleeding, abdominal pain, emesis, chronic diarrhea or signs of 
malabsorption [10, 18]. Occasionally, isolated intestinal neurofibromas may be the 
initial sign of NF1 in patients without any other clinical manifestations of the disease. 
As discussed previously, NF1 is a tumor predisposition syndrome and thus requires 
some degree of surveillance, consisting mainly of regular, comprehensive physical 
examinations aimed at the early detection and treatment of complications as they occur 
[19]. This case highlights the need for close clinical follow-up of patients found to have 
isolated neurofibromas to exclude NF1, as isolated neurofibromas are rare entities and 
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Fig. 2. Photomicrograph of a transverse colon polyp. A high-power field showed interlacing bundles 
of spindle cells, with comma-shaped nuclei, extending into the lamina propria, consistent with 
findings of a neurofibroma. Staining was positive for nuclear S100. 
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